Keywords
hepar cirrhosis, encephalopathy, ornithine, aspartate, larnamyn.
How to Cite
Moiseienko, V., Manzhalii, E., Solonovych, O., & Nykula, T. (2015). Features of the pathogenesis, diagnostics and treatment of hepatic encephalopathy in liver cirrhosis background. The Practitioner, (3), 30-35. Retrieved from https://plr.com.ua/index.php/journal/article/view/232
Abstract
The data on the positive experience with hepatic encephalopathy in patients with cirrhosis liver L-ornithine-L-aspartate (drug larnamyn), the effectiveness of which is provided by its components (amino acids, ornithine and aspartate) which improve metabolism, ammonia detoxification mechanism, production of energy in the Krebs cycle, promote restoration of the cell membrane, and carried out anti-inflammatory and detoxicative effect.
References
1. Bajaj J.S., Heuman D.M., Hylemon P.B. et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis // Aliment. Pharmacol. Ther. — 2014. — Vol. 39, N 10. — P. 1113-1125.
2. Bass N.M., Mullen K.D., Sigal S. et al. Rifaximin is Effective in Maintaining Remission in Hepatic Encephalopathy: results of a Large, Randomized, Placebo-Controlled // J. Hepatol. — 2009. — Vol. 50 (Suppl. 1). — P. 539.
3. Bass N.M., Mullen K.D. Rifaximin Treatment in Hepatic ncephalopathy // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1071-1081.
4. Ferenci P., Lockwood A., Mullen K. et al. Encephalopathy — Definition, Nomenclature, Diagnosis, and Quantification: Final Report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 // Hepatology. — 2002. — Vol. 35. — P. 716-721.
5. Hassanein T.I., Blei A.T., Perry W. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis // Am. J. Gastroenterol. — 2009. — Vol. 3 — P. 102.
6. Montagnese S., Amodio P., Morgan M.Y. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach // Metab. Brain Dis. — 2004. — Vol. 19. — P. 281-312.
7. Randolph C., Hilsabeck R., Kato A. et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines // Liver International. — 2009. — Vol. 29. — P. 629-635.
8. Sanyal A.J., Freedman A.M., Shiffman M.L. et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study // Hepatology. — 1994. — Vol. 20. — P. 46-55.
9. Wong F., O’Leary J.G., Reddy K.R. et al. North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection // Gastroenterology. — 2013. — Vol. 145, N 6. — P. 1280-1288.
2. Bass N.M., Mullen K.D., Sigal S. et al. Rifaximin is Effective in Maintaining Remission in Hepatic Encephalopathy: results of a Large, Randomized, Placebo-Controlled // J. Hepatol. — 2009. — Vol. 50 (Suppl. 1). — P. 539.
3. Bass N.M., Mullen K.D. Rifaximin Treatment in Hepatic ncephalopathy // N. Engl. J. Med. — 2010. — Vol. 362. — P. 1071-1081.
4. Ferenci P., Lockwood A., Mullen K. et al. Encephalopathy — Definition, Nomenclature, Diagnosis, and Quantification: Final Report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998 // Hepatology. — 2002. — Vol. 35. — P. 716-721.
5. Hassanein T.I., Blei A.T., Perry W. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis // Am. J. Gastroenterol. — 2009. — Vol. 3 — P. 102.
6. Montagnese S., Amodio P., Morgan M.Y. Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach // Metab. Brain Dis. — 2004. — Vol. 19. — P. 281-312.
7. Randolph C., Hilsabeck R., Kato A. et al. Neuropsychological assessment of hepatic encephalopathy: ISHEN practice guidelines // Liver International. — 2009. — Vol. 29. — P. 629-635.
8. Sanyal A.J., Freedman A.M., Shiffman M.L. et al. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study // Hepatology. — 1994. — Vol. 20. — P. 46-55.
9. Wong F., O’Leary J.G., Reddy K.R. et al. North American Consortium for Study of End-Stage Liver Disease. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection // Gastroenterology. — 2013. — Vol. 145, N 6. — P. 1280-1288.
Downloads
Download data is not yet available.